US pharmaceutical drug delivery market seen reaching $1.24 billion by 2031

The US Pharmaceutical Drug Delivery Market is projected to increase from USD 0.94 billion in 2026 to USD 1.24 billion by 2031, registering a CAGR of 5.8% during the forecast period. As chronic disease prevalence intensifies and advanced biologics reshape therapeutic standards, drug delivery technologies are becoming a strategic priority for pharmaceutical manufacturers, healthcare providers, and investors alike.

One of the primary forces behind market expansion is the growing prevalence of chronic conditions such as cancer and diabetes. At the same time, the increasing adoption of biologics, biosimilars, peptide therapies, monoclonal antibodies, and mRNA-based treatments is redefining how therapies must be delivered.

Modern drug delivery platforms, including lipid nanoparticles, autoinjectors, inhalers, transdermal patches, implantable systems, and controlled-release formulations, are essential to supporting advanced therapies such as cell and gene treatments. These systems are engineered to protect active ingredients during transit, deliver precise dosing, and improve therapeutic outcomes while minimizing systemic toxicity.

Based on route of administration, the injectable drug delivery segment is expected to grow at the highest CAGR during the forecast period. Advanced biologics and large-molecule drugs typically exhibit poor oral bioavailability and are highly sensitive to gastrointestinal degradation, making parenteral administration essential.

Innovations such as prefilled syringes, autoinjectors, depot injections, needle safety systems, and on-body wearable injectors are improving dosing accuracy, enhancing patient comfort, and reducing contamination risks. As pharmaceutical pipelines increasingly prioritize biologics, injectable delivery systems are positioned to remain at the forefront of therapeutic expansion.

By application, the cancer segment is projected to witness the highest CAGR through 2031. The rising incidence of cancer, coupled with broader adoption of targeted therapies and personalized medicine, is driving demand for advanced drug delivery mechanisms.

Oncology treatments frequently involve monoclonal antibodies, antibody-drug conjugates, biologics, and chemotherapeutics that require controlled and precise administration. Recent advancements, including implantable systems, long-acting depots, nanoparticle carriers, liposomal formulations, and on-body delivery platforms, enable localized, higher-concentration therapeutic delivery directly to tumor sites.

Based on care setting, the home care segment is expected to register the highest CAGR during the forecast period. Healthcare delivery in the US is shifting from hospital-centric models to outpatient and home-based care, with rising healthcare costs, patient preference for convenience, and expanded telemedicine infrastructure accelerating this transition.

Self-administration technologies, including autoinjectors, wearable injectors, prefilled syringes, connected smart devices, and on-body delivery systems, are enabling real-time adherence monitoring and reducing the need for frequent clinical visits. For chronic conditions such as diabetes, cancer, autoimmune disorders, and cardiovascular diseases, home-based drug delivery provides both clinical continuity and cost efficiency.

The market continues to face cost pressures. Drug-device combination products demand stringent quality control, specialized materials, and sophisticated engineering, while extended R&D timelines and increasingly rigorous regulatory approval processes around safety, usability, and device performance add complexity and financial burden for manufacturers.